![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NICE Recommends Gilead’s CAR-T Drug for Non-Hodgkin’s Lymphoma
NICE Recommends Gilead’s CAR-T Drug for Non-Hodgkin’s Lymphoma
December 17, 2018
The U.K.’s National Institute for Health and Care Excellence (NICE) recommended Gilead Sciences’ Yescarta (axicabtagene ciloleucel) to treat aggressive non-Hodgkin’s lymphoma for NHS coverage.
NICE cleared the CAR-T drug for reimbursement by the Cancer Drugs Fund. In securing the approval, Gilead beat out Novartis’ competing CAR-T therapy Kymriah, which has been approved for use in pediatric acute lymphoblastic leukemia but not this use.
The drug’s high cost initially prompted a rejection of coverage, but NHS England and the company have reached a confidential deal under which the medicine was deemed cost-effective.
Upcoming Events
-
21Oct